A detailed history of Agf Investments LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Agf Investments LLC holds 92,639 shares of EXEL stock, worth $3.35 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
92,639
Previous 53,541 73.02%
Holding current value
$3.35 Million
Previous $1.12 Million 30.31%
% of portfolio
0.13%
Previous 0.1%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

BUY
$15.68 - $22.27 $613,056 - $870,712
39,098 Added 73.02%
92,639 $1.45 Million
Q2 2022

Aug 12, 2022

BUY
$17.44 - $23.16 $205,826 - $273,334
11,802 Added 28.28%
53,541 $1.12 Million
Q1 2022

May 10, 2022

SELL
$17.03 - $22.67 $84,213 - $112,103
-4,945 Reduced 10.59%
41,739 $946,000
Q4 2021

Feb 01, 2022

BUY
$15.84 - $21.88 $224,104 - $309,558
14,148 Added 43.48%
46,684 $853,000
Q3 2021

Nov 10, 2021

BUY
$16.3 - $21.14 $88,574 - $114,874
5,434 Added 20.05%
32,536 $688,000
Q2 2021

Aug 12, 2021

BUY
$17.95 - $25.56 $486,480 - $692,727
27,102 New
27,102 $494,000
Q2 2020

Aug 11, 2020

SELL
$16.46 - $27.42 $65,823 - $109,652
-3,999 Closed
0 $0
Q1 2020

May 08, 2020

BUY
$14.46 - $21.8 $896 - $1,351
62 Added 1.57%
3,999 $69,000
Q4 2019

Feb 12, 2020

SELL
$15.15 - $18.89 $31,708 - $39,536
-2,093 Reduced 34.71%
3,937 $69,000
Q3 2019

Nov 12, 2019

BUY
$17.68 - $22.65 $106,610 - $136,579
6,030 New
6,030 $107,000
Q1 2018

May 04, 2018

SELL
$22.15 - $31.89 $14,707 - $21,174
-664 Closed
0 $0
Q4 2017

Feb 07, 2018

BUY
$24.23 - $30.93 $5,960 - $7,608
246 Added 58.85%
664 $20,000
Q3 2017

Nov 09, 2017

BUY
$23.35 - $29.24 $9,760 - $12,222
418
418 $11,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Agf Investments LLC Portfolio

Follow Agf Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Agf Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Agf Investments LLC with notifications on news.